Biologic drug survival in psoriasis reflects long-term performance in real-life settings. Previous studies have yielded inconsistent results.
We sought to analyze long-term biologic survival and its associated variables in a large, real-life cohort of patients with moderate to severe chronic plaque psoriasis.
This was an observational retrospective study. Data were extracted from clinical records of 427 patients treated with biologic agents over a 4-year period. Drug survival was analyzed using the Kaplan-Meier method and the influence of several covariates was assessed using Cox regression.
We analyzed 703 treatment courses. Overall median drug survival was 31.0 months. Cumulative probability of drug survival was lower in obese patients (23.0 months, 95% confidence interval 17.4-28.6) than in patients with body mass index less than 30 (37.3 months, 95% confidence interval 29.4-45.1, P = .001), and it was significantly higher for ustekinumab than for any other biologic agent (log rank test P < .001). Multivariate analysis showed that obesity, etanercept treatment, and strict adherence to approved doses were associated with an increased probability of drug withdrawal, whereas ustekinumab treatment, and PASI75 and PASI90 responses at week 16 prolonged drug survival.
Data were collected retrospectively.
These findings can facilitate the daily treatment of psoriatic patients and promote long-term effectiveness of biologic therapies.Le texte complet de cet article est disponible en PDF.
Key words : adalimumab, biologics: cohort, efficacy, etanercept, infliximab, psoriasis, real-life, survival, treatment, ustekinumab
Abbreviations used : ADA, BMI, CI, EMA, ETN, HR, IFX, PASI, SmPC, TNF, UST
| Supported by an unrestricted research grant (IISP-ORB-2013-84) from Novartis, Barcelona, Spain.
| Disclosure: Drs Vilarrasa, Notario, Bordas, and López-Ferrer have all received consultancy/speakers' honoraria and participated in clinical trials sponsored by Abbvie, Janssen, MSD, Novartis, and Pfizer. Dr Puig has received consultancy/speakers' honoraria and participated in clinical trials sponsored by Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, and Pfizer. Dr Gich has no conflicts of interest to declare.